Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cofrogliptin vs Linagliptin Add-on in T2DM
NCT07019012Phase 4Recruiting
- Sponsor
- Huazhong University of Science and Technology
- Start
- Jul 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cofrogliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Huazhong University of Science and Technology. Primary endpoint: Change in glycated hemoglobin (HbA1c) levels at 24 weeks. Started Jul 2025; status: recruiting.
02
Drugs
cofrogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07019012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07019012.